Monitoring and treatment of iron overload: state of the art and new approaches.
Porter
J B
JB
University College London, Department of Haematology, London, UK. j.porter@ucl.ac.uk
D001565:Benzoates / Q000494:pharmacology / Q000627:therapeutic use; D000077588:Deferasirox; D000077543:Deferiprone; D003676:Deferoxamine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D005293:Ferritins / Q000097:blood / Q000737:chemistry; D006485:Hemosiderin / Q000737:chemistry; D006801:Humans; D007501:Iron / Q000032:analysis / Q000378:metabolism; D007502:Iron Chelating Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D019190:Iron Overload / Q000175:diagnosis* / Q000188:drug therapy*; D008099:Liver / Q000737:chemistry; D008279:Magnetic Resonance Imaging / Q000379:methods; D008280:Magnetics; D011728:Pyridones / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use
D001565:Benzoates; D007502:Iron Chelating Agents; D011728:Pyridones; D014230:Triazoles; D000077543:Deferiprone; D005293:Ferritins; D006485:Hemosiderin; D007501:Iron; D003676:Deferoxamine; D000077588:Deferasirox